Evaluating Stomach Function with Body Surface Gastric Mapping in Adults Using Semaglutide Ozempic

What this Trial Is About

Researchers are investigating the effects of Semaglutide Ozempic, a glucagon-like receptor-1 agonist used for diabetes and weight management, on gastric motility and symptoms. This observational study aims to understand the changes in gastric myoelectrical activity and gastrointestinal symptoms in patients with and without diabetes using a novel non-invasive diagnostic device called Gastric Alimetry. The study builds on initial findings that showed abnormal gastric activity and severe bloating after Semaglutide use. Participants will undergo Body Surface Gastric Mapping using the FDA-approved Gastric Alimetry device before and after starting weekly injectable Semaglutide treatment. The study will compare gastric function and symptom changes from baseline to three months on treatment. This approach seeks to identify accurate non-invasive biomarkers of gastric dysfunction related to Semaglutide use. During the study, participants will have assessments of gastric myoelectrical activity and report their symptoms using several scales over three months. Researchers will monitor changes in gastric rhythm, symptom severity, quality of life, anxiety, stress, and other patient-reported outcomes. The primary outcome is the change in post-meal Gastric Alimetry Rhythm Index. The study will provide insight into gastric function alterations linked to Semaglutide use and their symptoms.

Body Surface Gastric Mapping in Patients on Semaglutide